ATN-161

ATN 161

ATN-161;ATN161;1-Acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-L-aspartamide;Ac-Pro-His-Ser-Cys-Asn-NH2, PHSCN (Modifications: Pro-1 = N-terminal Ac, Asn-5 = C-terminal amide);Ac-PHSCN-NH2;ATN 161;XW0H5LE42K;(S)-2-((R)-2-((S)-2-((S)-2-((S)-1-acetylpyrrolidine-2-carboxamido)-3-(1H-imidazol-5-yl)propanamido)-3-hydroxypropanamido)-3-mercaptopropanamido)succinamide;AOB2958;(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-acetylpyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amin;ATN-161 free base;CCG-270186;DA-71103;(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-acetylpyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]butanediamide;L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-;Alpha V Beta 1 Inhibitor ATN-161;ATN-161?;262438-43-7;BS-16323;Ac-Pro-His-Ser-Cys-Asn-NH2;SCHEMBL2157375;HY-13535;262438-43-7 (free base);SCHEMBL17262996;DTXCID00103368;DTXSID60180877;Acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide;D83668;UNII-XW0H5LE42K;GLXC-04869;ATN-161 (Ac-PHSCN-NH2);BRD-K00521308-019-01-9;(2S)-2-(((2R)-2-(((2S)-2-(((2S)-2-(((2S)-1-ACETYLPYRROLIDINE-2-CARBONYL)AMINO)-3-(1H-IMIDAZOL-4-YL)PROPANOYL)AMINO)-3-HYDROXY-PROPANOYL)AMINO)-3-SULFANYL-PROPANOYL)AMINO)BUTANEDIAMIDE;AKOS030210988;(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-{[(2S)-1-acetylpyrrolidin-2-yl]formamido}-3-(1H-imidazol-4-yl)propanamido]-3-hydroxypropanamido]-3-sulfanylpropanamido]succinamide;(S)-2-((R)-2-((S)-2-((S)-2-((S)-1-Acetylpyrrolidine-2-carboxamido)-3-(1H-imidazol-4-yl)propanamido)-3-hydroxypropanamido)-3-mercaptopropanamido)succinamide;AKOS040732486;s8454;CHEMBL4297456;CS-3327

262438-43-7

C₂₃H₃₅N₉O₈S

597.64

ATN-161 (Ac-PHSCN-NH2)是一由纤连蛋白的协同区域衍生出的五氨基酸短肽；具有抗肿瘤活性的β整合素拮抗剂。